SR9011

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
SR9011
SR9011.svg
Identifiers
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
Formula C23H31ClN4O3S
Molar mass 479.03524 g/mol
3D model (JSmol)

SR9011 is a research drug that was developed by Professor Thomas Burris of Scripps as an agonist of Rev-ErbAα with a half-maximum inhibitory concentration (IC50) = 790 nM for Rev-Erbα and IC50 = 560 nM for Rev-ErbAβ.[1]

See also[edit]

References[edit]

  1. ^ Solt LA; Wang Y; Banerjee S; Hughes T; Kojetin DJ; Lundasen T; Shin Y; Liu J; Cameron MD; Noel R; Yoo SH; Takahashi JS; Butler AA; Kamenecka TM; Burris TP (May 2012). "Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists". Nature. 485 (7396): 62–8. doi:10.1038/nature11030. PMC 3343186. PMID 22460951. Lay summaryNature Magazine.